Impact Therap-b (07630.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 4.31B

MomentumView details →

1D Return

+4.07%

YTD Return

—

RSI (14)

54.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 4.31B

RSI (14)

54.5

MomentumView details →

1D Return

+4.07%

YTD Return

—

ProfitabilityView details →

Gross Margin

80.07%

Net Margin

−770.57%

EBITDA Margin

−583.07%

ROE (TTM)

55.88%

ROA (TTM)

−160.02%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−59.98%

EPS CAGR 3Y

+16.67%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.05

EPS Surprise

−48.03%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

−48.03%

Rev Surprise

−89.27%

Capital & dividendView details →

Debt/Equity

−0.90x

Current Ratio

3.08x

Quick Ratio

2.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

9.94M

Net Income (TTM)

−76.59M

Op. CF (TTM)

−25.58M

Next earningsMar 3, 2027 →

Latest newsMore news →

Impac Pharma issued a profit warning on August 11, 2026, expecting H1 2026 revenue of approximately 94.7 million to 116 million yuan, up 276%-359% year-on-year, and a net loss of 81.7 million to 99.9 million yuan, narrowing 22%-37% from the prior year.24d ago

Similar companies

Tong Ren Tang Technologies Co. Ltd.01666.HK Organon & Co.OGN 神奇制药600613.SH Grifols, S.A.GRFS 广誉远600771.SH Luye Pharma Group Ltd.02186.HK Find similar companies →

Latest newsMore news →

Impac Pharma issued a profit warning on August 11, 2026, expecting H1 2026 revenue of approximately 94.7 million to 116 million yuan, up 276%-359% year-on-year, and a net loss of 81.7 million to 99.9 million yuan, narrowing 22%-37% from the prior year.24d ago